Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

As the demand for precise analytical data in the biotechnology sector reaches new heights, Lyze Labs is positioning itself as ...

First national call is LIVE for new biotech fund under the Centre’s RDI initiative, signalling India’s big bet on Bioeconomy ...

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

Feed additives suit intensive farms but different solutions for methane reduction are needed for pasture-raised cattle, says ...

A reversal of cuts to the National Institutes of Health budget has life sciences operators breathing a sigh of relief.

Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain Moderna's narrower-than-expected loss, why healthcare is outperforming, and vaccine mandates and ...

BIRAC plans key regulatory changes to accelerate biotech innovation, supported by new funding initiatives and increased industry collaboration.

We take a look at Oxford’s biotech and life sciences hub to discover what makes this historical city a hotspot for scientific ...